RSV Clinical Trial
Official title:
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF 3 LOTS OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN HEALTHY ADULTS
This randomized, double-blinded, placebo-controlled Phase 3 study is designed to evaluate the safety, tolerability, and immunogenicity of 3 lots of RSVpreF in healthy adults.
This randomized, double-blinded, placebo-controlled Phase 3 study will examine the immune response and the safety and tolerability profiles across 3 manufactured lots of RSVpreF when administered as a single 120 µg dose to healthy adults to demonstrate lot equivalence in manufacturing of RSVpreF. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06160128 -
COVID-19 Pharmacotherapy Effectiveness in the VA Healthcare System
|
||
Completed |
NCT05585632 -
A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old
|
Phase 1 | |
Completed |
NCT05778240 -
Adherence to Palivizumab Prophylaxis
|
N/A | |
Recruiting |
NCT01985620 -
The Impact of a Short Intervention During RSV Prophylaxis on Influenza Vaccination Rate.
|
N/A |